FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 01/2021”.
The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.
As of the end of January 2021, we identify the following current VC trends in the US-Biotech sector:
- In 2021, overall Biotech funding in the USA has reached USD 3,055m so far
- Top 5 deals exceed USD 100m each, largest transaction amounted to USD 525m in EQRx, Inc.
- ARCH Venture Partners (USA) dominates the Top 5 Investors (by deal volume), followed by Alexandria Venture Investments (USA) and HLB (South Korea)
- Oncology dominates as the top indication
To access the full report, please click here.